Alzamend Neuro Inc Stock News

Neuroscience 2026, the annual meeting of the Society for Neuroscience, will be held November 14–18, 2026   in Washington, DC Presentation Title: Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial ATLANTA, Aug. 20, 2026 /PRNewswire/ -- Alzamend Neuro, Inc.  (Nasdaq: ALZN) ("Alz...

ISMRM Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR will be held September 28 – October 1, 2026   at the Universitat Oberta de Catalunya (UOC) in Barcelona, Spain Presentation will report first-of-its-kind pharmacokinetic imaging results from Phase 1/2A trial of AL001, Alzamend's novel organic lithium drug candidate, in healthy human subjects ATLANTA, Aug. 18, 2026 /PRNewsw...

Company received $7.5 million in gross proceeds from the initial tranche of Series D Convertible Preferred Stock Agreement provides for up to $17.5 million in additional funding through subsequent tranche closings to support Alzamend's clinical programs and working capital needs ATLANTA, Aug. 4, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceu...

Potentially Distinct Brain Profile: Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a distinct manner and generate a lower neurochemical footprint than lithium carbonate Expected Trends for Myo-Inositol Reduction : Both AL001 and lithium carbonate showed a trend ...